BioSyent Expands with Tibelia Asset Acquisition
Company Announcements

BioSyent Expands with Tibelia Asset Acquisition

Story Highlights

Biosyent (TSE:RX) has released an update.

BioSyent Pharma Inc. has acquired the assets for Tibelia, a hormone replacement therapy drug, from Novalon SA and Mithra Pharmaceuticals SA, including intellectual property and global distribution rights, for up to EUR 2.8 million. This move is expected to bolster the company’s earnings by approximately 12% and aligns with BioSyent’s strategic goals of growth and diversification. Tibelia has been a key product in BioSyent’s women’s health portfolio since 2020, and with this acquisition, they can now supply it globally.

For further insights into TSE:RX stock, check out TipRanks’ Stock Analysis page.

Related Articles
Austin AngeloIs RX a Buy, Before Earnings?
Ryan AdistBiosyent (RX) Discloses Q3 Dividend: What Shareholders Should Know
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App